For example, one study found that 52 weeks after stopping once-weekly semaglutide injections, participants had regained 66% of their prior weight loss
More seriously, they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), and they must be used carefully in patients with a history of pancreatitis or certain gallbladder conditions
Some people find that this kind of medication decreases their sense of thirst in addition to hunger
GLP-1 RAs, which have been approved by the U.S
In contrast, drugs like Mounjaro and Ozempic have gained attention for their more pronounced weight loss effects, with Mounjaro being a dual agonist that also targets the GIP receptor, potentially enhancing efficacy but also increasing the risk of gastrointestinal side effects
Do Van, B